OSMR

OSMR Molekülinformation

Englischer Name	Oncostatin-M-specific receptor subunit beta	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	IL-31R-beta，IL-31RB，Interleukin-31 receptor subunit beta，IL-31 receptor subunit beta，IL-31R subunit beta
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Oncostatin-M-specific receptor subunit beta
Target-Alias	IL-31R-beta，IL-31RB，Interleukin-31 receptor subunit beta，IL-31 receptor subunit beta，IL-31R subunit beta
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

OSMR Produktliste

Attribut
Protein (5)
Produktbibliothek
Online (5)
Spezies
Cynomolgus (1)Human (3)Canine (1)
Etikett
His Tag (3)His Tag & Avi Tag (1)Fc Tag (1)
Marker
Unconjugated (4)Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT OSR-C52H9	Cynomolgus	HEK293	Cynomolgus OSMR beta Protein, His Tag, low endotoxin (MALS verified)	In den Warenkorb legen
OSR-H5253	Human	HEK293	Human OSMR beta Protein, Fc Tag, low endotoxin (MALS verified)	In den Warenkorb legen
OSR-H52H9	Human	HEK293	Human OSMR beta Protein, His Tag, low endotoxin (MALS verified)	In den Warenkorb legen
OSR-H82E3	Human	HEK293	Biotinylated Human OSMR beta Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen
OSR-C52H8	Canine	HEK293	Canis lupus OSMR beta Protein, His Tag (MALS verified)	In den Warenkorb legen

Gesamtmenge5

OSMR Molekülhintergrund

Oncostatin-M-specific receptor subunit beta (OSMRβ), also known as Interleukin-31 receptor subunit beta (IL-31RB), is the beta subunit of the type II OSM receptor, which is a heterodimer of gp130 and OSMRβ. OSMRβ associates with the low-affinity OSM·gp130 complex to form a high-affinity heterodimeric receptor that is capable of transducing OSM-specific signaling events.

OSMR Molekülalias

Oncostatin-M-specific receptor subunit beta,Interleukin-31 receptor subunit beta,IL-31 receptor subunit beta,IL-31R subunit beta,IL-31R-beta,IL-31RB,OSMR,OSMRB

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Vixarelimab	KPL-716; BIIB-069; RG-6536; RO-7622888	Phase 2 Clinical	Biogen Inc	Chronic Urticaria; Colitis, Ulcerative; Lichen Planus; Neurodermatitis; Plaque psoriasis; Prurigo Nodularis; Pruritus	Details